Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 2/20 | 0.45 |
| ▸ | CKS1B | P61024 | 2/20 | 0.42 |
| ▸ | SKP1 | P63208 | 2/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.41 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.41 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3947538 | 0.87 | HTR6 (0.47) | BACE1CKS1BSKP1SKP2ACHE | |
| SCHEMBL4135821 | 0.82 | HTR6 (0.51) | CHRM2CHRM1 | |
| SCHEMBL3949857 | 0.81 | PIK3CA (0.53) | PIK3CACKS1BSKP1SKP2GPR119 | |
| SCHEMBL3948268 | 0.80 | PARP1 (0.44) | BACE1CKS1BSKP1SKP2ACHE | |
| SCHEMBL8243476 | 0.79 | ACHE (0.48) | BACE1CKS1BSKP1SKP2ACHE | |
| SCHEMBL3952445 | 0.79 | HTR6 (0.56) | — | |
| SCHEMBL3831589 | 0.76 | PIK3CA (0.51) | PIK3CABACE1CKS1BSKP1SKP2 | |
| SCHEMBL5203019 | 0.74 | HTR6 (0.46) | PIK3CABACE1CKS1BSKP1SKP2 | |
| SCHEMBL3951206 | 0.74 | BACE1 (0.47) | BACE1CKS1BSKP1SKP2ACHE | |
| SCHEMBL5202405 | 0.74 | HTR6 (0.70) | PIK3CABACE1CKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253711-A1 | HETEROCYCLYL-3-SULFONYLINDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090253711-A1 | HETEROCYCLYL-3-SULFONYLINDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090253711-A1 | HETEROCYCLYL-3-SULFONYLINDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2009-10-08 | — | — | US | disclosed |
| US-7560470-B2 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560470-B2 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560470-B2 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-07-14 | — | — | US | disclosed |
| US-20070232618-A1 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070232618-A1 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070232618-A1 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-10-04 | — | — | US | disclosed |
| US-7238696-B2 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238696-B2 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-07-03 | — | — | US | disclosed |
| US-20040167122-A1 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | WYETH | 2004-08-26 | — | — | US | disclosed |
| US-20040167122-A1 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | WYETH | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232618-A1 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | HTR6, HTR2C, HTR3B | PIK3CA 4566/4885BACE1 2386/4885CKS1B 4358/4885 |
| US-20090253711-A1 | HETEROCYCLYL-3-SULFONYLINDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | HTR6, HTR2C, HTR3B | PIK3CA 4566/4885BACE1 2386/4885CKS1B 4358/4885 |
| US-20040167122-A1 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | HTR6, HTR1A, HTR2C | PIK3CA 4573/4885BACE1 2092/4885CKS1B 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.